Similar efficacy of lopinavir/ritonavir-containing regimens among clades B and F HIV-1-infected individuals in Brazil

被引:6
|
作者
Diaz, Ricardo Sobhie [1 ]
Vasconcelos, Lucy [2 ]
Hayden, Ricardo L. [3 ]
Tenore, Simone [1 ]
Turcato, Gilberto, Jr. [1 ]
Palacios, Ricardo [1 ]
Sucupira, Maria C. [1 ]
机构
[1] Univ Fed Sao Paulo, Sao Paulo, Brazil
[2] Prefeitura Municipal Sao Paulo, Sao Paulo, Brazil
[3] Santa Casa Santos, Santos, Brazil
关键词
D O I
10.1097/QAI.0b013e31815b0d48
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
引用
下载
收藏
页码:399 / 401
页数:3
相关论文
共 50 条
  • [11] Concentration-response Model of Lopinavir/Ritonavir in HIV-1-infected Pediatric Patients
    Bouazza, Naim
    Urien, Saik
    Blanche, Stephane
    Hirt, Deborah
    Foissac, Frantz
    Benaboud, Sihem
    Treluyer, Jean-Marc
    Frange, Pierre
    PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2014, 33 (08) : E213 - E218
  • [12] Predictive factors of virologic success in HIV-1-infected children treated with lopinavir/ritonavir
    Delaugerre, C
    Teglas, JP
    Treluyer, JM
    Vaz, P
    Jullien, V
    Veber, F
    Rouzioux, C
    Chaix, ML
    Blanche, SP
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2004, 37 (02) : 1269 - 1275
  • [13] The NIQ of lopinavir is predictive of a 48-week virological response in highly treatment-experienced HIV-1-infected subjects treated with a lop inavir/ritonavir-containing regimen
    Castagna, A
    Gianotti, N
    Galli, L
    Danise, A
    Hasson, H
    Boerr, E
    Hoetelmans, R
    Nauwelaers, D
    Lazzarin, A
    ANTIVIRAL THERAPY, 2004, 9 (04) : 537 - 543
  • [14] Pharmacokinetics of a once-daily regimen of lopinavir/ritonavir in HIV-1-infected children
    van der Lee, Manon
    Verweel, Gwenda
    de Groot, Ronald
    Burger, David
    ANTIVIRAL THERAPY, 2006, 11 (04) : 439 - 445
  • [15] Treatment outcomes amongst previously antiretroviral-naive HIV-infected patients starting lopinavir/ritonavir-containing antiretroviral regimens at the Royal Free Hospital
    Smith, C. J.
    Phillips, A. N.
    Youle, M. S.
    Sabin, C. A.
    Lampe, F. C.
    Tsintas, R.
    Tyrer, M.
    Johnson, M. A.
    HIV MEDICINE, 2007, 8 (01) : 55 - 63
  • [16] Drug monitoring and viral response to lopinavir/ritonavir or saquinavir/ritonavir containing regimens in individuals infected with the human immunodeficiency virus type1
    Falkensammer, B
    Fasser, W
    Scherer, K
    Zemann, A
    Parson, W
    Ulmer, H
    Dierich, MP
    Stoiber, H
    INTERNATIONAL JOURNAL OF IMMUNOPATHOLOGY AND PHARMACOLOGY, 2005, 18 (01) : 145 - 154
  • [17] Changes in body fat composition after 1 year of salvage therapy with lopinavir/ritonavir-containing regimens and its relationship with lopinavir plasma concentrations
    Gutiérrez, F
    Padilla, S
    Masiá, M
    Navarro, A
    Gallego, J
    Hernández, I
    Ramos, JM
    Martin -Hidalgo, A
    ANTIVIRAL THERAPY, 2004, 9 (01) : 105 - 113
  • [18] The effect of fluconazole on ritonavir and saquinavir pharmacokinetics in HIV-1-infected individuals
    Koks, CHW
    Crommentuyn, KML
    Hoetelmans, RMW
    Burger, DM
    Koopmans, PP
    Mathôt, RAA
    Mulder, JW
    Meenhorst, PL
    Beijnen, JH
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2001, 51 (06) : 631 - 635
  • [19] Similar Safety and Efficacy of Once- and Twice-Daily Lopinavir/Ritonavir Tablets in Treatment-Experienced HIV-1-Infected Subjects at 48 Weeks
    Zajdenverg, Roberto
    Podsadecki, Thomas J.
    Badal-Faesen, Sharlaa
    Andrade-Villanueva, Jaime
    Gathe, Joseph
    Mingrone, Horacio
    Fredrick, Linda M.
    Gaultier, Isabelle A.
    Woodward, W. Chris
    Bernstein, Barry M.
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 54 (02) : 143 - 151
  • [20] Efficacy of indinavir-ritonavir-based regimens in HIV-1-infected patients with prior protease inhibitor failures
    Campo, RE
    Moreno, JN
    Suarez, G
    Miller, N
    Kolber, MA
    Holder, DJ
    Shivaprakash, M
    DeAngelis, DM
    Wright, JL
    Schleif, WA
    AIDS, 2003, 17 (13) : 1933 - 1939